Targeted therapies in osteoarthritis: a systematic review of the trials on www.clinicaltrials.gov

Best Practice and Research: Clinical Rheumatology

Volumn 24, Issue 1, 2010, Pages 107-119

  Berenbaum, Francis ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

biotherapy; osteoarthritis; systematic review; targeted therapies

Indexed keywords

AGG 523; AS 902330; BALICATIB; BRADYKININ B2 RECEPTOR; CANNABINOID 2 RECEPTOR; CAPSAICIN; CATHEPSIN K; CELECOXIB; DICLOFENAC; FIBROBLAST GROWTH FACTOR 18; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR ANTAGONIST; GW 842166; ICATIBANT; INDUCIBLE NITRIC OXIDE SYNTHASE; LY 545694; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; NAPROXEN; NERVE GROWTH FACTOR; NITRIC OXIDE SYNTHASE INHIBITOR; OSTEOGENIC PROTEIN 1; PF 04383119; PG 110; PLACEBO; SD 6010; TANEZUMAB; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; KNEE PAIN; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); OSTEOARTHRITIS; UNITED STATES;

EID: 74549131535     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2009.08.007     Document Type: Review

References (24)

1. Michon M, Sellam J, Berenbaum F. Targeted therapies in osteoarthritis. In: Weisman Michael H, Weinblatt Michael E, Louie James S, van Vollenhoven Ronald F, (editors), Targeted Treatment of Rheumatic Diseases. Vol. 1 (in press).
2. Hefti F.F., Rosenthal A., Walicke P.A., et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 27 2 (2006 Feb) 85-91
3. Seidel M.F., Herguijuela M., Forkert R., et al. Nerve growth factor in rheumatic diseases. Sem Arthritis Rheum (2009 May 27)
4. Whiteside G.T., Lee G.P., and Valenzano K.J. The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem 14 8 (2007) 917-936
5. Guindon J., and Hohmann A.G. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153 2 (2008 Jan) 319-334
6. Andreou A.P., Holland P.R., and Goadsby P.J. Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation. Br J Pharmacol 157 3 (2009 Jun) 464-473
7. Nilius B., Voets T., and Peters J. TRP channels in disease. Sci STKE 2005 295 (2005 Aug 2) re8
8. Stuckya C.L., Dubinb A.E., Jeskec N.A., et al. Roles of transient receptor potential channels in pain. Brain Res Rev 60 (2009) 2-23
9. Remadevi R., and Szallisi A. Adlea (ALGRX-4975), an injectable capsaicin (TRPV1 receptor agonist) formulation for long-lasting pain relief. IDrugs 11 2 (2008 Feb) 120-132
10. Meini C.A. Maggi Knee osteoarthritis: a role for bradykinin?. Inflamm Res 57 (2008) 351-361 S
11. Cawston T.E., and Wilson A.J. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 20 5 (2006 Oct) 983-1002
12. Krzeski P, Buckland-Wright C, Balint G, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG 116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12 month, double-blind, placebo-controlled study. Arthritis Res Ther 2007;9:R109.
13. Boileau C., Martel-Pelletier J., Brunet J., et al. Oral treatment with PD-0200347, an alpha2delta ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. Arthritis Rheum 52 2 (2005 Feb) 488-500
14. Salminen-Mankonen H.J., Morko J., and Vuorio E. Role of Cathepsin K in normal joints and in the development of arthritis. pp. 315-323 (9). Curr Drug Targets 8 2 (2007 Feb) 315-323
15. Chubinskaya S., Hurtig M., and Rueger D.C. OP-1/BMP-7 in cartilage repair. Int Orhop 31 6 (2007) 773-781
16. Moore E.E., Bendele A.M., Thompson D.L., et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 13 7 (2005) 623-631
17. Granholm S., Lundberg P., and Lerner U.H. Expression of the calcitonin receptor, calcitonin receptor-like receptor, and receptor activity modifying proteins during osteoclast differentiation. J Cell Biochem 104 3 (2008 Jun 1) 920-933
18. Karsdal M.A., Sondergaard B.C., Arnold M., et al. Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis?. Ann N Y Acad Sci 1117 (2007 Nov) 181-195
19. Holick M.F. Vitamin D deficiency. N Engl J Med 357 3 (2007 Jul 19) 266-281
20. Jacques C., Gosset M., Berenbaum F., et al. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm 74 (2006) 371-403
21. Chevalier X., Goupille P., Beaulieu A.D., et al. Intra-articular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 61 3 (2009 Mar 15) 344-352
22. Feldmann M., and Maini S.R. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 223 (2008 Jun) 7-19
23. Madi L., Cohen S., Ochayin A., et al. Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. J Rheumatol 34 1 (2007 Jan) 20-26
24. Lane N.E., Schnitzer T.J., and Brown M.T. Tanezumab relieves moderate to severe pain due to Osteoarthritis (OA) of the knee: a phase 2. Trial Arthritis Rheum (2008) (Suppl.)